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By letter of 13 February 1990 the Council consulted the European Parliament, 
pursuant to Article 100a of the EEC Treaty, on the Commission proposal for a 
Council directive concerning the legal status of the supply of medicinal 
products for human use. 
At the sitting of 12 March 1990 the President of Parliament announced that he 
had referred this proposal to the Committee on the Environment, Public Health 
and Consumer Protection as the committee responsible and to the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Budgets for their opinions. 
At its meeting of 23 March 1990 the Committee on the Environment, Public 
Health and Consumer Protection appointed Mrs Ceci rapporteur. 
At its meetings of 9 November 1990, 18 December 1990, 31 January 1991 and 
25 April 1991 it considered the Commission proposal and draft report. 
At the last meeting it adopted the draft legislative resolution by 20 votes 
to nil with 2 abstentions. 
The following took part in the vote: Collins, chairman; Schleicher and 
Iversen, vice-chairmen; Ceci, rapporteur; Alber, Banotti, Bombard, Bowe, 
Chanterie, Di Rupo, Florenz, Guidolin, Hadjigeorgiou (for Douste-Blazy), 
Caroline Jackson, Kuhn, Muscardini, Pimenta, Pollack, Roth-Behrendt, 
Schwartzenberg, Valverde Lopez, Vertemati. 
The op1n1ons of the Committee on Economic and Monetary Affairs and Industrial 
Policy and the Committee on Budgets are attached. 
The report was tabled on 30 April 1991. 
The deadline for tabling amendments will appear on the draft agenda for the 
part-session at which the report is to be considered. 
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A 
Commission proposal for a Council directive concerning the legal status 
for the supply of medicinal products for human use 
Commission text1 Amendments 
(Amendment No. 1) 
Title 
Proposal for a Council directive 
concerning the legal status for the 
supply of medicinal products for 
human use. 
Proposal for a Council directive 
concerning the legal status for the 
supply of medicinal products for 
human use and their classification. 
(Amendment No. 2) 
Second recital a, b and c (new) 
Whereas Chapter III of Part 3 of the 
Annex to Directive 75/318/EEC lays 
down the special conditions for the 
supply of medicinal products where 
advisable in the light of test 
results; 
Whereas the supply of medicinal 
products is a professional activity 
which guarantees the protection of 
the health of consumers and includes 
t ·h e p r o y i s i o n o f a d e g u a t e 
information on the proper use of the 
medication; 
Whereas the conditions for supply of 
medicinal prqducts must be based on 
objective criteria established by 
evaluation of the products under 
normal conditions of use. 
1For full text see OJ No. C 58, 8.3.1990, p. 19 
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(Amendment No. 3) 
Fourth recital 
Whereas, moreover, persons moving 
around within the Community have the 
right to carry a reasonable quantity 
of medicinal products legitimately 
obtained for their personal use; 
whereas it must also be possible for 
a person established in one Member 
State to receive from another Member 
State a reasonable quantity of 
medicinal products intended for his 
personal use; whereas it is 
important therefore to harmonize the 
conditions of delivery of medicinal 
products to the public; 
Whereas, moreover, persons moving 
around within the Community have the 
right to carry a reasonable quantity 
of medicinal products legitimately 
obtained for their personal use; 
whereas it must also be possible for 
a person established in one Member 
State to receive from another Member 
State a reasonable quantity of 
medicinal products intended for his 
personal use; 
(Amendment No. 4) 
Sixth recital 
Whereas it is therefore appropriate, 
in a first stage, to harmonize the 
basic principles applicable to the 
legal status for the supply of 
medicinal products in the Community 
or in the Member State concerned, 
while taking as a starting point the 
principles already established on 
this subject by the Council of 
Europe as well as the work of 
harmonization completed within the 
framework of the United Nations, 
concerning narcotics and 
psychotropics, 
Whereas, in order to harmonize the 
legal status for the supply of 
medicinal products, it is necessary 
for the Community to define the 
categories of medicines for which a 
prescription is compulsory and those 
which may be sold over the counter; 
whereas this definition shall take 
account of the principles already 
established on this subject by the 
Council of Europe as well as the 
work of the United Nations 
concerning narcotic and psychotropic 
substances; 
(Amendment No. 5) 
Sixth recital a (new) 
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Whereas, in order to guarantee 
consumer safety and the liability 
of undertakings, no medicine may be 
supplied other than by pharmacies or 
other establishments expressly 
authorized to do so on the grounds 
that they provide specific 
guarantees of safety (as regards 
storage and hygiene conditions and 
staff qualified to dispense to the 
public); 
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Commission text Amendments 
(Amendment No. 6) 
Article 1 ( 1 ) 
1. This Directive concerns the 
legal status for the supply of 
medicinal products for human use in 
the Community. 
1. This Directive concerns the 
legal status for the supply of 
medicinal products for human use and 
their classification in the 
Community as: 
- medicinal prqducts subject to 
medical prescription. 
- medicinal products not subject 
to medical prescription. 
(Amendment No. 7) 
Article 1(2) 
2. For the purpose of this Council 
Directive, the definition of 
'medicinal product' in Article 1 of 
Council Directive 65/65/EEC shall 
apply. 
2. For the purpose of this Council 
Directive, the definition of 
'medicinal product' set out in 
Article 1 of Council Directive 
65/65/EEC shall apply. 
In addition, 
'legal status for supply' shall 
mean: the conditions under which 
a medicinal product may be 
supplied to the public by a 
professional who is qualified 
under the terms of Directive 
85/432/EEC and 85/433/EEC; 
'medical prescription' shall 
mean: anv prescription emanating 
from a professional qualified to 
prescribe medicinal products. 
(Amendment No. 8) 
Article 1a(new) 
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1 a. A prescription duly issued in 
one Member State in a~cordance with 
its legislation may be presented in 
any other Member State. except where 
expressly prohibited in respect of a 
specific medicinal product. 
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Commission text Amendments 
2. In order to ensure the general 
effectiveness of the prescription. 
ayoid errors in prescription and 
supply and ensure the proper use of 
the medicinal product, the 
prescription shall consist of two 
parts: 
the prescription itself; intended 
for the pharmacist, which must 
contain, except for iustified 
reasons. the diagnosis or 
diagnostic information and basic 
information concerning the 
patient's general state of health 
which might give rise to side 
effects or contra-indications; 
the set of instructions for the 
patient consisting of two 
sections: one to be filled out 
by the prescribing doctor, 
including indications relevant to 
the treatment, and the other to 
be filled out by the pharmacist. 
giving the necessary instructions 
for the orooer use and 
administration of the medicinal 
product in each case. 
(Amendment No. 9) 
Article 2 
Medicinal products which may only be 
available on medical prescription, 
shall be classified at the time of 
granting the authorization for 
marketing, in one of the following 
categories: 
(a) medicinal products on 
prescription, which may be 
renewed during a period of six 
months from the date of the 
prescription, unless otherwise 
specified; 
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1. When a marketing authorization is 
granted, the competent authority 
shall specify the classification 
of the medicinal product: 
medicinal product subject to 
medical prescription. 
medicinal product not subject to 
medical prescription. 
To this end the criteria laid down 
in Article 3(1) shall apply. 
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Commission text 
(b) medicinal products on 
prescription, which may not be 
renewed without the 
prescriber's express consent; 
(c) medicinal products on special 
prescription, containing a 
substance classified as a 
psychotropic or a narcotic 
substance within the meaning of 
the international conventions 
in force (conventions of the 
United Nations of 1961 and 
1971 ) ; 
(d) medicinal products on limited 
prescription, reserved: 
for use in hospitals, 
to certain specialists. 
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Amendments 
2. The competent authorities shall 
specify the subcategories of 
medicinal pr9ducts which can only 
be supplied on medical 
prescription. In this case they 
shall use the following 
classification: 
(a) medicinal products available on 
renewable or non-renewable 
medical prescription. 
(b)medicinal pr9ducts subject to 
special medical prescription. 
(c)medicinal products available on 
restricted medical prescription 
reserved for certain specialized 
areas. 
3. The medical prescription shall 
not in itself be considered to be 
a yalid certificate for the 
purpose of reimbursement by 
national health services. In any 
case. national provisions and 
those operating within the 
framework of existing Community 
cooperation agreements (E111 > 
regarding payments and 
reimbursements in respect of 
medicinal products. will continue 
to aooly. 
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Commission text Amendments 
(Amendment No. 10). 
Article 3(1) 
1 . When a marketing authorization 
is granted, the competent authority 
shall specify the legal status for 
the supply of the medicinal 
product: 
- medicinal product not subject to 
medical prescription. 
- medicinal product subject to 
medical prescription, mentioning 
one of the categories referred to 
in Article 2. 
To this end, the criteria laid down 
in Article 4 shall apply. 
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1.Medicinal products hall be subject 
to medical prescription where: 
they present a danger, directly 
or indirectly, eyen under normal 
conditions of use if taken 
without medical supervision or 
they are used frequently and to a 
yery large extent under the wrong 
conditions and this is likely to 
cause a direct or indirect danger 
to health or 
they contain substances or 
preparations based on substances 
whose effects and/or side effects 
require more detailed research or 
they are administered 
parenterally or 
they cause addiction and/or 
dependence. 
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Commission text Amendments 
(Amendment No. 11) 
Article 3(2) 
2. All medical products containing a 
new chemical shall be subject to 
medical prescription, and classed 
in one of the categories referred to 
in Article 2. 
DOC_EN\RR\109021 - 10 -
2 . Where Member States specify a 
subcategory of medicinal product 
subject to special medical 
prescription. account shall be taken 
of the following elements: 
the presence in the medicinal 
product of a non-exempted dosage 
of a substance classified as a 
psychotropic or a narcotic 
substance within the meaning of 
the releyant international 
conventions (United Nations 
Conventions of 1961 and 19711 or 
the possibility that the 
medicinal product could, if 
improperly used. give rise to 
major risks of medicinal abuse. 
cause addiction or be misused for 
illegal purposes.or 
the presence in the medicinal 
product of a substance which, 
because of its noyel ty or 
properties. could be included in 
that category as a precautionary 
measure. 
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Commission text Amendments 
(Amendment No. 12) 
Article 3(2a)(new) 
2a. In cases where Member States 
specify a subcategory of medicinal 
products Subject to limited medical 
prescript ion, they shall take 
account of the following elements 
medicinal products which, by 
reason of their pharmacological 
characteristics or their novelty 
or in the interest of public 
health, are reserved for use in 
treatments which can only be 
carried out in hospitals. 
medicinal products employed in 
the treatment of illnesses which 
reauire diagnosis in a hospital 
or other institution with 
adequate facilities for 
diagnosis. but where 
administration and follow-up can 
be carried out outside the 
hospital or in establishments 
equipped with adequate diagnostic 
facilities. 
medicinal products for use by 
out-patients which could produce 
seyere adverse effects and which 
therefore call for supervised 
treatment. 
(Amendment No. 13) 
Article 3(3) 
3. The competent authority shall 
publish at least annually the list 
of medicinal products subject to 
medical prescription, specifying the 
category of classification. 
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The competent authority shall 
publish at least annually the list 
of medicinal products subject to 
medical prescription specifying the 
category of classification and 
circulate this list to the medical 
professionals in their territory. 
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Commission text Amendments 
(Amendment No. 14) 
Article 3a(new) 
3a. Medicinal products not subject 
to prescription shall be those which 
do not correspond to the criteria 
listed in Article 3. 
(Amendment No. 15) 
Article 4, new paragraph before paragraph 1 
The legislation concerning the 
suooly of a medicinal product and 
its classification shall be set out 
in the authorization certificate and 
included with the list of properties 
of the medicinal pr9duct. 
(Amendment No. 16) 
Article 4(1) 
1. Medicinal products which contain 
substances which are likely to 
present a direct or indirect danger 
to human health, even under normal 
conditions of use, shall not be 
supplied to the public without 
medical prescription. The following 
criteria shall be taken into 
consideration in this respect: 
1. Medicinal products which contain 
substances which are likely to 
present a serious direct or indirect 
danger to human health, even under 
normal conditions of use, shall not 
be supplied to the public without 
medical prescription. The following 
criteria shall be taken into 
consideration in this respect. 
(Amendment No. 17) 
Article 4(1)(c) 
(c) possibility of serious side 
effects in normal conditions of 
use; 
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(c) the possibility and frequency 
of serious side effects in normal 
conditions of use; 
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Commission text Amendments 
(Amendment No. 18) 
Article 4(1)(d) 
(d) serious risks associated with 
c on t r a - i n d· i c a t i on s a n d 
precautions for use; 
(d) serious risks associated with 
contra-indications and 
precautions in normal 
conditions of use, if it is 
imoossible to specify clearly 
the groups at risk; 
(Amendment No. 19) 
Article 4(1)(e) 
(e) indications requ1r1ng a medical 
diagnosis or special medical 
supervision; 
(e) indications requiring special 
medical supervision; 
(Amendment No. 20) 
Article 4(1)(f) 
(f) harmfulness of constituents 
under normal conditions of use, 
taking into account posology, 
pack size or possible 
excessively extended treatment; 
(f) harmfulness of constituents 
under normal conditions of use, 
taking into account possible 
limitations in respect of 
posology, pack size, 
instructions for use and means 
of administration; 
(Amendment No. 21) 
Article 4(1)(g) 
(g) parenteral administration, 
except when very long term 
illness reguires an active 
participation by the patient in 
the treatment (for example 
diabetes); 
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Deleted. 
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Commission text Amendments 
(Amendment No. 22) 
Article 5(1) 
1. Within two years of the adoption 
of this Directive, the Member 
States shall communicate to the 
Commission and to the other Member 
States the list of medicines which 
are available only on medical 
prescription on their territory, 
mentioning the category of 
classification. 
1. Within two years of the adoption 
of this Directive, the competent 
authorities of the Member States 
shall publish the list of medicinal 
pr9ducts which are available only on 
medical prescription in their 
territory, mentioning the category 
of classification. They shall 
publish this list annually. 
(Amendment No. 23) 
Article 5(2) 
2. Each year Member States shall 
communicate to the Commission and to 
the other Member States the changes 
that have been made to the list 
referred to in paragraph 1. 
2. Each year Member States shall 
communicate to the Commission and to 
the other Member States the list 
referred to in paragraph 1 and the 
changes that have been made thereto. 
(Amendment No. 24) 
Article 5 ( 3) 
3. Within fQy£ years of adoption of 
this Directive, the Commission shall 
submit a report to the Council on 
the application of this Directive. 
This report will be accompanied, if 
necessary, by appropriate proposals. 
3. Within five years of adoption of 
this Directive, the Commission shall 
draw up a list of the medicinal 
products in all Member States which 
are available only on medical 
prescription. The list shall apply 
to all Member States. 
(Amendment No. 25) 
Article 5(3a)(new) 
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3a. Within five years of adoption 
of this Directiye, the Commission 
shall draw up a list of the 
medicinal products in all the Member 
States which are available without 
medical prescription. This list 
shall apply to all the Member 
States. 
PE 146.241/fin. 
Commission text 
DOC_EN\RR\109021 
Amendments 
(Amendment No. 26) 
Article 5a(new) 
5a. No provision of this Directive 
may result in the monopoly of the 
distribution of medicinal products 
to the Public granted to pharmacists 
in certain Member States being 
challenged. 
(Amendment No. 27) 
Article 56 (new) 
- 15 -
5b. The provisions of this 
Directive shall have neither the 
objective nor effect of challenging 
the rules established by each Member 
State on the refunding by the social 
security authorities of the cost of 
medicinal pr9ducts. 
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A 
DRAFT LEGISLATIVE RESOLUTION 
(Cooperation procedure: first reading) 
embodying the opinion of the European Parliament on the Commission proposal 
for a Council directive concerning the legal status for the supply of 
medicinal products for human use 
The European Parliament, 
- having regard to the Commission proposal to the Council (COM(89) 0607 final 
- SYN 230) 1, 
- having been consulted by the Council pursuant to Article 1 OOa of the EEC 
Treaty (C3-0049/90), 
- having regard to the report of the Committee on the Environment, Public 
Health and Consumer Protection and the opinions of the Committee on 
Economic and Monetary Affairs and Industrial Policy and the Committee on 
Budgets (A3-0Hll4/91), 
1. Approves the Commission proposal subject to Parliament's amendments and 
in accordance with the vote thereon; 
2. Calls on the Council to incorporate Parliament's amendments in the common 
position that it adopts in accordance with Article 149(2)(a) of the EEC 
Treaty; 
3. Instructs its President to forward this opinion to the Council and 
Commission. 
1 OJ No. C 58, 8.3.1990, p. 19 
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B 
EXPLANATORY STATEMENT 
This Directive proposes to harmonize conditions of distribution to patients 
which at present appear to vary considerably. 
The main differences between the Member States lie in: 
(a) the regulations governing the supply of medicinal products to the public 
on medical prescription, 
(b) the differing provisions on whether medicinal products may be dispensed 
to the public in pharmacies only or whether they are also available from 
other establishments including supermarkets. 
The reasons for the diversification of the drugs market as outlined above can 
be attributed only in part to actual medical considerations such as allowing 
consumers to have more control and greater responsibility and enabling them to 
obtain rapidly tried and tested drugs with which they are familiar. 
Other reasons are attributable to: 
(a) the provisions of the health and social security systems which tend only 
to reimburse (or supply directly) medicinal products prescribed by 
medical officers, 
(b) the diversification of industrial production which identifies over the 
counter drugs as a more dynamic market sector which is less subject to 
protectionism and more in line with the laws of free competition 
(advertising, which is usually prohibited in the case of prescription-
only medicines, is permitted in respect of over the counter medicines). 
The rapporteur considers that a fundamental choice must be made when 
attempting to rationalize the conditions for administering drugs, namely, that 
consumer safety must be made paramount, in accordance with Article 1 OOa of 
the EEC Treaty. In practice, this means fulfilling certain specific 
criteria, namely: 
1. Confirming the ethical nature of pharmacological treatment; this means 
that the responsibility of the prescribing medical officer, which is a 
feature of sales of medicinal products compared with other categories of 
products, must be fully recognized. 
2. Ensuring that none of the safety and quality requirements governing the 
supply of medicinal products is jeopardized at any stage of the 
distribution chain (for example, through the sale of products in 
establishments other than pharmacies which are not subject to supervision 
by qualified staff and which do not provide adequate guarantees as 
regards storage conditions and hygiene). 
3. Ensuring that 1 safe 1 medicinal products are widely available to all 
Community citizens, by recognizing everywhere the legal value of a 
medical prescription. 
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4. Preserving traditional therapeutic practices which have become firmly 
established in response to specific social and cultural conditions, 
provided that they do not run counter to the primary objective of safety; 
5. Combating abuses relating to over-prescription and self-administration, 
by laying down special provisions in those sectors in which such abuses 
are most widespread or most dangerous. 
These considerations form the basis of the proposed amendments, and are aimed 
at ensuring that the supply of medicinal products from pharmacies on 
presentation of a medical prescription recognized as having a period of 
validity of 6 months and having legal value throughout the Member States is 
the standard method of supply to the public. 
It is the duty of the medical worker who prescribes the medicinal product to 
decide (on the basis not only of the type of medicine but also of the 
pathology and clinical symptoms of the individual patient) whether or not the 
prescription should be repeated and, if so, how many times within the given 
period. 
It is the duty of the pharmacist to ensure compliance with the prescription 
and to combat abuses. 
This system does not apply to over the counter medicines. In defining such 
medicines, it appears inadvisable to depart as the Commission does in its 
proposal from universally-recognized criteria - such as a well-established 
market and use limited to the treatment of easily recognizable symptoms 
capable of rapid relief. In particular, it seems inadvisable to introduce a 
third category of drugs (a 'grey area') which does not correspond to over the 
counter products but which is defined as a category of medicinal products 
which can also be obtained without a medical prescription. 
This third category cannot be justified on either scientific grounds or on the 
grounds of consumer safety. 
It is indeed necessary to guard against the emergence of a heterogeneous group 
of medicaments which are dispensed in various Member States without a medical 
prescription. These, we repeat, have no medical or scientific justification 
and simply cater to the requirement of cheaper medicines which is now 
widespread in all the Member States as a result of the uncontrolled expansion 
of the pharmaceuticals market. 
The legal status for the supply of medicinal products and the conditions for 
reimbursement to the public must therefore remain absolutely separate issues, 
particularly in the spirit and letter of the Directive in question. 
The rapporteur recognizes that the proposed amendments differ substantially in 
some respects from the Commission proposal. 
However, they offer certain advantages: 
- Member States are not required to agree on a list, however minimal, of 
medicinal products obtainable only on a medical prescription based on 
criteria on which no general agreement has yet been reached; 
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no unacceptable changes are made in respect of current prescription 
practice, while long-established regulations governing particular 
categories of medicines are maintained; 
mention is made of the future system of registering medicinal products in 
accordance with the requirement of technical and scientific assessment; 
the marketing of medicinal products is made transparent but not static; it 
does not penalize the industry's activities but at the same time it ensures 
total respect for consumer safety. 
It is therefore suggested that this important directive be approved, subject 
to the proposed amendments. 
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OPINION 
(Rule 120 of the Rules of Procedure) 
of the Committee on Economic and Monetary Affairs and Industrial Policy 
for the Committee on the Environment, Public Health and Consumer Protection 
Craftsman: Mr SISO CRUELLAS 
At its meeting of 27 June 1990, the Committee on Economic and Monetary 
Affairs and Industrial Policy appointed Mr SISO CRUELLAS draftsman. 
At its meetings of 26-28 June, 25 and 27 September and 15-16 October 1990, the 
committee considered the draft opinion. It adopted its conclusions by 20 
votes to none, with one abstention. 
The following took part in the vote: Beumer, chairman; Fuchs, vice-chairman; 
Siso Cruellas, draftsman; Cassidy, Cox, Ernst de la Graete, Herman, Lulling, 
Merz, Metten, Pinxten, Rogalla, Speciale, Amaral (for de Donnea), Martinez 
(for Megret), Nielsen (for Visentini), Peter (for Ford), Randzio-Plath (for 
Hoff) , Ti tley (for Seal) , Van der Waal (for Lataillade) and Navarro (for 
Gallenzi) pursuant to Rule 111(2).' 
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I. Proposal for a directive concerning the legal status for the supplv of 
medicinal products for human use 
1. Contents of the proposal 
(a) The present situation 
The conditions of supply of medicinal products for human use vary 
considerably between Member States. Certain medicinal products which 
are freely on sale in some Member States can only be obtained on 
prescription in others. 
However, persons circulating in the Community have the right to carry a 
reasonable quantity of medicinal products for their personal use. It is 
also permitted to import by post a reasonable quantity of medicinal 
products for personal use2 . To facilitate the exercise of these rights 
while preventing their abuse, it is therefore desirable to harmonize the 
criteria for the classification of medicinal products. 
(b) The proposed measures 
The directive therefore lays down the criteria applicable to the legal 
status for the supply of medicinal products in the Community or the 
Member State concerned. It also categorizes medicinal products on the 
basis of type of prescription (Article 2), specifies the arrangements 
for publication and revision of the lists of medicinal products subject 
to prescription (Article 3) and the conditions of supply of medicinal 
products without prescription (Article 4). These criteria are based on 
principles which have already been established in this area by the 
Council of Europe and the UN. 
2. Comments 
In view of its subject-matter, this directive has a number of aspects. 
It will certainly make it easier for the Community citizen to use the 
medicinal products that he needs wherever he happens to be in the 
Community. In this context, the directive should clarify the 
arrangements and conditions of sale of medicinal products which are not 
subject to prescription. It also deals with the regulation of the 
advertising of pharmaceuticals, which will be the subject of a 
forthcoming Commission proposal. 
It would, however, be exaggerated to suppose that this proposal will 
lead to rapid harmonization of the different statuses for the supply of 
medicinal products, since these reflect the different medical cultures 
and traditions rooted in the societies of the Member States. 
This directive, however, represents a first step towards a more 
harmonious conception of medicinal products in professional circles. 
2 European Court reports: Schumacher case, 215/87, 7 March 1989 
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It requires, nonetheless, a number of modifications or further 
specifications, with regard, in particular to the list of categories of 
prescription (Article 2) and to the arrangements for the revision of 
the list of medicinal products subject to prescription (under which 
insufficient protection is granted to manufacturers' rights ) (Article 
3; no provision is made for justification of decisions of the 
authorities or for appeal procedures). In addition, the criteria for 
the supply of medicinal products should be determined on the basis of 
the different categories of prescription (Article 4). 
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DRAFT AMENDMENTS 
Proposal for a directive concerning the legal status for the supply of 
medicinal products for human use 
Amendment No. 8 
Article 2 (former Article 3) to read: 
1. When a marketing authorization 
is granted, the competent 
authority shall specify the 
legal status for the supply of 
the medicinal product: 
medicinal product not subject 
to medical prescription, 
medicinal product subject to 
medical prescription, 
mentioning one of the 
categories referred to in 
Article 1. 
To this end, the criteria laid down 
in Article 4 shall apply. 
2. 
3. 
All medical products 
containing a new chemical 
entity shall be subject to 
medical prescription, and 
classed in one of the 
categories referred to in 
Article 1. 
The competent authority shall 
publish at least annually the 
list of medicinal products 
subject to medical 
prescription specifying the 
category of classification. 
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1. Unchanged except for second 
indent: 
- medicinal product subject to 
medical prescription, mentioning 
one of the categories referred to 
in Article J. 
2.All medical products containing a 
new chemical or biological entity 
shall be subject to medical 
prescription, and classed in one 
of the categories referred to in 
Article ,l. 
3.Unchanged. 
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4. On the occasion of the 5-yearly 
renewal of the marketing 
authorization or when new 
scientific elements are 
communi ea ted to them, the 
competent authorities shall 
examine and, as appropriate, may 
amend the legal status for the 
supply of a medicinal product, by 
applying the criteria listed in 
Article 4. 
4. Unchanged 
5. (new) 
Where the specification or 
alteration of the legal status for 
the supply of a medicinal product 
takes place independently of the 
marketing authorization or its five-
yearly renewal, the competent 
authorities in the Member States 
shall decide on the basis of 
Article 3 and the present article 
and shall publish the decisions. 
Appeal procedures in respect of 
these decisions shall be established 
and brought to the notice of the 
holders of marketing authorizations. 
Amendment No. 9 
Article 3 (former Article 2) to read: 
Medicinal products which may only be 
available on medical prescription 
shall be classified, at the time of 
granting the authorization for 
marketing, in one of the following 
categories: 
(a) 
(b) 
medicinal products on 
prescription, which may be 
renewed during a period of six 
months from the date of the 
prescription, unless otherwise 
specified; 
medicinal products on 
prescription, which may not be 
renewed without the 
prescriber's express consent; 
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Unchanged. 
(a) medicinal products on 
prescription, which may be 
renewed during a period of three 
months from the date of the 
prescription, unless otherwise 
specified; 
(b) Unchanged. 
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(c) 
(d) 
medicinal products on special 
prescription, containing a 
substance classified as a 
psychotropic or a narcotic 
substance within the meaning 
of the international 
conventions in force 
(conventions of the United 
Nations of 1961 and 1971); 
medicinal products on 
restricted prescription, 
reserved 
for use in hospitals, 
to certain specialists. 
(c) medicinal products containing 
non-exempted dosages of a 
substance classified as a 
psychotropic or a narcotic 
substance within the meaning of 
the international conventions in 
force (conventions of the United 
Nations of 1961 and 1971); • 
(d) medicinal products on restricted 
prescription, reserved 
- for use in hospitals, 
- for diagnosis in hospitals, 
-for prescription by 
specialists. 
Amendment No. 10 
Article 4(1) 
1. Medicinal products which contain 
substances which are likely to 
present a direct or indirect 
danger to human health, even 
under normal conditions of use, 
shall not be supplied to the 
public without medical 
prescription. The following 
criteria shall be taken into 
consideration in this respect: 
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1 . Unchanged. 
1.1. Criteria determining whether a 
medicinal product shall be 
supplied only on prescription: 
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• 
(a) potential risks appearing during 
the preclinical and clinical 
tests and trials; 
(b) novelty of the active principle, 
as stated in Article 3, 
paragraph 2; 
(c) possibility of serious side 
effects in normal conditions of 
use; 
(d) serious risks associated with 
contra-indications and 
precautions for use; 
(e) indications requiring a medical 
diagnosis or special medical 
supervision; 
(f) harmfulness of constituents 
under normal conditions of use, 
taking into account posology, 
pack size or possible 
excessively extended treatment; 
(g) parenteral administration, 
except when very long term 
illness requires an active 
participation by the patient in 
the treatment (for example 
diabetes); 
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(a) Unchanged 
(b) novelty of the active principle, 
as stated in Article 1_, 
paragraph 2; 
(c) Unchanged. 
(d) Unchanged. 
(e) Unchanged. 
(f) Unchanged. 
(g) Unchanged. 
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(h) important risk of abuse, 
addiction or misuse for criminal 
purposes 
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1.2. Criteria determining whether a 
medicinal product shall be 
supplied onlv on prescription 
within the terms of Article 
J..W1. 
Chl treatment of chronic 
disorders where 
administration does not 
require the 
prescriber's suoerv1s1on 
during the period of 
validity of the 
prescription. which 
shall be longer than the 
period corresponding to 
the contents of one 
P2£1L. 
1.3. Criteria determining whether a 
medicinal product shall be 
suoolied only on prescription 
within the terms of Article 
~ 
( i) important risk of abuse, 
addiction or misuse for 
criminal purposes 
because the product 
contains substances 
classified as 
psychotropic or 
narcotic substances or 
substances which, in 
view of their novelty or 
properties, could be 
included in that 
category as a 
precautionary measure. 
1.4. Criteria determining whether a 
medicinal product shall be 
supplied only on prescription 
within the terms of Article 
~ 
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(j) Use in hospitals: 
Medicinal products which, 
by reason of their 
pharmacological 
characteristics or their 
novelty. or in the 
interests of public 
health. are reserved for 
use in treatments which 
can only be carried out in 
hospitals; 
(k) Diagnosis in hospitals: 
Medicinal products 
employed in the treatment 
of illnesses which require 
diagnosis in a hospital or 
other institution with 
adequate facilities for 
diagnosis, even where the 
administration and follow-
up can be carried out on 
an out-patient basis; 
(1) Prescription by 
specialists: 
Medicinal products for 
use by out-patients which 
could produce severe 
adverse effects. and which 
therefore call for 
supervised treatment. 
1 . 5 Criteria determining whether a 
medicinal product shall be 
supplied only on prescription 
within the terms of Article 
ll.Q.l.l. 
(m) where the provisions of 
subparagraphs (kl and (1 l 
above do not apply for the 
medicinal product to be 
supplied on prescription in 
accordance with paragraph 
1.1 of the present article. 
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Amendment No. 11 
Article 4(2) 
2. Kcreover, medical products which 
may be available without 
prescription shall show a 
substantial safety in use in the 
treatment of minor ailments or 
symptoms, usually capable of 
rapid and spontaneous relief, 
which are easily identifiable by 
users and do not justify a 
medical consultation. 
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2. (first word deleted) Medical 
products which may be available 
without prescription shall show 
a substantial safety in use in 
the treatment of minor ailments 
or symptoms, usually capable of 
rapid and spontaneous relief, 
which are easily identifiable by 
users and do not justify a 
medical consultation. 
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CONCLUSION 
The three proposals for directives are aimed at rationalizing the distribution 
of medicinal products for human use in order to facilitate their circulation 
in conditions offering the highest possible security to the patient. 
They are consequently in line with the objective of creating a large unified 
market in a sector which has hitherto been relatively compartmentalized. 
Proposal concerning the legal status for the supply of medicinal products 
for human use 
The conditions of supply of medicinal products for human use vary 
considerably between Member States, according to whether or not the 
products concerned are subject to prescription. This situation is an 
obstacle to the harmonization of the use of medicinal products in the 
Community. It is therefore to be welcomed that the directive lays down, 
in particular the criteria applicable to the legal status for the supply 
of medicinal products for human use (categories of medicinal product 
according to type of prescription; arrangements for the publication and 
revision of lists of medicinal products). 
However, some of the provisions seem to be unnecessarily complicated (as 
in the case of the prescription categories). In addition, there is 
insufficient protection of manufacturers' rights in the event of revision 
of the list; prov1s1on should be introduced for the justification of 
decisions and for appeal procedures. 
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0 P I N I 0 N 
of the Committee on Budgets 
Letter from the Chairman of the committee to the Chairman of the Committee on 
the Environment, Public Health and Consumer Protection 
Subject: Proposal for a Council directive concerning the legal status for the 
supply of medicinal products for human use 
(COM(89) 607 final) 
Dear Mr Chairman, 
At its meeting of 1 June 1990 the Committee on Budgets considered the above 
proposal. 
After considering the nature of the proposal and its financial consequences, 
the Committee on Budgets decided to deliver a favourable opinion thereon. 
Yours faithfully, 
(sgd) Thomas von der VRING 
The following were present for the vote: von der Vring, chairman; Arias 
Caiiete, Boge, Colajanni, Colom I Naval, Elles, Kellet-Bowman, Langes, Lo 
Giudice, McCartin (for Forte), Miranda da Silva, Pasty, Theato, Tomlinson and 
Wynn. 
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